Opinion

Video

Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
4 experts are featured in this series.
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
John Ostrominski, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo